Genentech, Inc.

Newlink Genetics Corporation

Brendan Parr

Lewis J Gazzard

Zhonghua Pei

Richard Pastor

Po-Wai Yuen

Firoz Jaipuri

Rohan V Mendonca

Sanjeev Kumar

Guosheng Wu

Wendy Liu

Xingyu Lin

Hima Potturi

Jesse Waldo

Benjamin Douglas Sellers

Yanyan Chu

Xiaokai Li

Guoshen Wu

Roheeth Pavana

Powai Yuen

Venkata Velvadapu

Zuhui Zhang

Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 and IDO1 inhibitors

Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer. 

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 Inhibitors

Growing community of inventors

South San Francisco, CA, United States of America

Brendan Parr